» Articles » PMID: 35075772

Genes Regulated by DNA Methylation Are Involved in Distinct Phenotypes During Melanoma Progression and Are Prognostic Factors for Patients

Abstract

In addition to mutations, epigenetic alterations are important contributors to malignant transformation and tumor progression. The aim of this work was to identify epigenetic events in which promoter or gene body DNA methylation induces gene expression changes that drive melanocyte malignant transformation and metastasis. We previously developed a linear mouse model of melanoma progression consisting of spontaneously immortalized melanocytes, premalignant melanocytes, a nonmetastatic tumorigenic, and a metastatic cell line. Here, through the integrative analysis of methylome and transcriptome data, we identified the relationship between promoter and/or gene body DNA methylation alterations and gene expression in early, intermediate, and late stages of melanoma progression. We identified adenylate cyclase type 3 (Adcy3) and inositol polyphosphate 4-phosphatase type II (Inpp4b), which affect tumor growth and metastatic potential, respectively. Importantly, the gene expression and DNA methylation profiles found in this murine model of melanoma progression were correlated with available clinical data from large population-based primary melanoma cohorts, revealing potential prognostic markers.

Citing Articles

LncRNAs in melanoma phenotypic plasticity: emerging targets for promising therapies.

Beatriz Cristina Biz T, Carolina de Sousa C, Frank John S, Miriam Galvonas J RNA Biol. 2024; 21(1):81-93.

PMID: 39498940 PMC: 11540095. DOI: 10.1080/15476286.2024.2421672.


Identification of SLC22A17 DNA methylation hotspot as a potential biomarker in cutaneous melanoma.

Lavoro A, Falzone L, Gattuso G, Conti G, Caltabiano R, Madonna G J Transl Med. 2024; 22(1):887.

PMID: 39358721 PMC: 11445995. DOI: 10.1186/s12967-024-05622-9.


Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future Perspectives.

Hossain S, Carpenter C, Eccles M Int J Mol Sci. 2024; 25(13).

PMID: 39000359 PMC: 11241335. DOI: 10.3390/ijms25137252.

References
1.
Conway K, Edmiston S, Parker J, Kuan P, Tsai Y, Groben P . Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis. J Invest Dermatol. 2018; 139(6):1349-1361. PMC: 6535139. DOI: 10.1016/j.jid.2018.11.024. View

2.
Borcherding N, Bormann N, Voigt A, Zhang W . TRGAted: A web tool for survival analysis using protein data in the Cancer Genome Atlas. F1000Res. 2018; 7:1235. PMC: 6173115. DOI: 10.12688/f1000research.15789.2. View

3.
Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

4.
Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

5.
Ibarrola-Villava M, Cervantes A, Bardelli A . Preclinical models for precision oncology. Biochim Biophys Acta Rev Cancer. 2018; 1870(2):239-246. DOI: 10.1016/j.bbcan.2018.06.004. View